Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$14.94 -3.2%	$14.32	$5.74 ▼ $17.15	$405.31M	0.44	43,778 shs	270,605 shs
CMPS COMPASS Pathways	$4.80 +7.1%	$4.01	$2.49 ▼ $8.54	$419.16M	2.25	920,182 shs	3.06 million shs
MREO Mereo BioPharma Group	$2.87 +2.5%	$2.41	$1.58 ▼ $5.02	$445.20M	0.47	1.09 million shs	1.11 million shs
THTX Theratechnologies	$2.50 +1.6%	$2.60	$1.12 ▼ $3.13	$113.11M	0.6	816,385 shs	112,605 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	-3.24%	-9.78%	+6.87%	-11.02%	+106.07%
CMPS COMPASS Pathways	+7.14%	+4.58%	+10.34%	+62.16%	-25.35%
MREO Mereo BioPharma Group	+2.50%	+8.30%	+25.33%	+12.11%	-27.89%
THTX Theratechnologies	+1.63%	-1.96%	-4.21%	+54.32%	+89.39%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	2.5465 of 5 stars	3.6	2.0	0.0	0.0	2.9	2.5	0.0
CMPS COMPASS Pathways	2.1436 of 5 stars	3.5	3.0	0.0	0.0	1.3	0.8	0.6
MREO Mereo BioPharma Group	2.1266 of 5 stars	3.6	1.0	0.0	0.0	3.4	1.7	0.0
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.22	Buy	$23.83	59.53% Upside
CMPS COMPASS Pathways	3.00	Buy	$18.83	292.36% Upside
MREO Mereo BioPharma Group	3.17	Buy	$7.67	167.13% Upside
THTX Theratechnologies	4.00	Strong Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest THTX, MREO, CMPS, and BNTC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$12.00
5/19/2025	BNTC Benitec Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/15/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$20.00 ➝ $20.00
5/13/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/12/2025	CMPS COMPASS Pathways	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$45.00 ➝ $45.00
4/11/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
4/10/2025	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$18.00 ➝ $20.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/28/2025	CMPS COMPASS Pathways	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00

(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$80K	4,902.19	N/A	N/A	$4.68 per share	3.19
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	$2.26 per share	N/A
MREO Mereo BioPharma Group	$10M	45.63	N/A	N/A	$0.39 per share	7.36
THTX Theratechnologies	$85.87M	1.34	N/A	N/A	($0.55) per share	-4.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$21.75M	-$1.51	N/A	N/A	N/A	N/A	-38.26%	-35.71%	N/A
CMPS COMPASS Pathways	-$155.12M	-$1.99	N/A	N/A	N/A	N/A	-81.75%	-59.42%	7/30/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.08	N/A	35.71	N/A	-4.18%	N/A	-0.37%	7/9/2025 (Estimated)

Latest THTX, MREO, CMPS, and BNTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q3 2025	BNTC Benitec Biopharma	-$0.36	-$0.24	+$0.12	-$0.24	N/A	N/A
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
5/8/2025	Q1 2025	CMPS COMPASS Pathways	-$0.47	-$0.44	+$0.03	-$0.24	N/A	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
CMPS COMPASS Pathways	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	14.80	14.80
CMPS COMPASS Pathways	0.11	10.18	10.18
MREO Mereo BioPharma Group	N/A	8.92	8.92
THTX Theratechnologies	N/A	1.08	0.88

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
CMPS COMPASS Pathways	46.19%
MREO Mereo BioPharma Group	62.83%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	1.30%
CMPS COMPASS Pathways	3.93%
MREO Mereo BioPharma Group	5.50%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	20	26.25 million	25.91 million	No Data
CMPS COMPASS Pathways	120	93.56 million	89.89 million	Optionable
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

THTX, MREO, CMPS, and BNTC Headlines

Recent News About These Companies

Theratechnologies Inc. (NASDAQ:THTX) Short Interest Update

June 2, 2025 | marketbeat.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

Theratechnologies to further evaluate potential sale of the company

April 16, 2025 | markets.businessinsider.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | financialpost.com

Theratechnologies Provides Update on Sale Process

April 15, 2025 | globenewswire.com

Theratechnologies Engages in Exclusive Acquisition Talks

April 15, 2025 | tipranks.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | financialpost.com

Soleus Capital Issues Letter to The Board of Theratechnologies

April 12, 2025 | businesswire.com

Theratechnologies Responds to Future Pak's Press Release and Announces Exclusive Discussions with Another Potential Acquiror for the Sale of the Company

April 11, 2025 | globenewswire.com

Future Pak submits proposals to acquire Theratechnologies

April 11, 2025 | msn.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc. ...

April 11, 2025 | gurufocus.com

Future Pak Submits Proposals to Acquire Theratechnologies Inc., Offering up to $255 Million in Total Value

April 11, 2025 | businesswire.com

Theratechnologies Stock Plummets On Disappointing Q1 Earnings, Full Year Forecast: Retail Sentiment Sours

April 9, 2025 | msn.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies Reports Financial Results for the First Quarter 2025 and Reviews Key Achievements

April 9, 2025 | globenewswire.com

Theratechnologies receives FDA approval of PAS for EGRIFTA SV sBLA

April 8, 2025 | markets.businessinsider.com

3THTX : Examining the Future: Theratechnologies's Earnings Outlook

April 8, 2025 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THTX, MREO, CMPS, and BNTC Company Descriptions

Benitec Biopharma NASDAQ:BNTC

$14.94 -0.50 (-3.24%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$14.94 0.00 (-0.03%)

As of 06/18/2025 04:46 PM Eastern

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

COMPASS Pathways NASDAQ:CMPS

$4.80 +0.32 (+7.14%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$4.96 +0.17 (+3.44%)

As of 06/18/2025 07:52 PM Eastern

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.

Mereo BioPharma Group NASDAQ:MREO

$2.87 +0.07 (+2.50%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.86 -0.01 (-0.35%)

As of 06/18/2025 07:48 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Theratechnologies NASDAQ:THTX

$2.50 +0.04 (+1.63%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$2.50 0.00 (0.00%)

As of 06/18/2025 05:42 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time